Glut-1 Expression Correlates with Basal-like Breast Cancer

Hussein, Youssef; Bandyopadhyay, Sudeshna; Semaan, Assaad; Ahmed, Quratulain; Albashiti, Bassam; Jazaerly, Tarek; Nahleh, Zeina; Ali-Fehmi, Rouba

doi:10.1593/tlo.11256

Cited by 71 publications

(70 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, as GDH activity is influenced by various factors, it is presumed that GDH activity is not directly proportional to glutamine uptake by ASCT2 or GLS activity. Furthermore, basal-like type and/or TNBC has been shown to exhibit the highest glycolysis-related protein activity, including Glut1 (SLC2A1) and CAIX (CA9) (Hussein et al 2011, Pinheiro et al 2011. Taken together, the low level of GDH activity observed in TNBC in this study can be explained by its high level of glycolytic activity.…”

Section: Discussionmentioning

confidence: 49%

“…Therefore, metabolic status is also expected to differ according to molecular subtype. Previous studies support this expectation, having identified aerobic glycolysisrelated proteins such as GLUT1 (SLC2A1) and CAIX (CA9), which are highly expressed in basal-like type and/or triple-negative breast cancer (TNBC; Hussein et al 2011, Pinheiro et al 2011). However, relatively few studies have considered differences in glutamine metabolism according to the molecular subtypes of breast cancer.…”

Section: Introductionmentioning

confidence: 82%

See 1 more Smart Citation

Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer

Kim¹,

Kim

Jung

et al. 2013

Endocrine-Related Cancer

126

View full text Add to dashboard Cite

The aim of this study was to investigate the expression of glutamine metabolism-related proteins to determine whether glutamine is metabolized differently according to breast cancer molecular subtype. We generated a tissue microarray of 702 breast cancer patients and performed immunohistochemical staining for glutamine metabolism-related proteins, including glutaminase 1 (GLS1 (GLS)), glutamate dehydrogenase (GDH (H6PD)), and amino acid transporter-2 (ASCT2 (SLC1A5)), which were separately evaluated in tumor and stroma compartments and then analyzed by breast cancer molecular subtypes. Breast cancers were classified as follows: 293 luminal A (41.7%), 166 luminal B (23.6%), 67 HER2 type (9.6%), and 176 TNBC (25.1%). HER2 type showed the highest stromal GLS1 (PZ0.001), tumoral GDH (PZ0.001), stromal GDH (P!0.001), and tumoral ASCT (P!0.001) expression. We identified differential expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. The highest glutamine metabolic activity was seen in HER2-type breast cancer.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Introductionmentioning

confidence: 82%

Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer

Kim¹,

Kim

Jung

et al. 2013

Endocrine-Related Cancer

126

View full text Add to dashboard Cite

show abstract

“…3 Previous studies indicated that upregulation of GLUT-1 contributed to an improved glucose metabolism, which was required in proliferating cancer cells. 2 GLUT-1 is overexpressed in many tumors, including breast, 4 colorectal, 5 endometrial, 6 and ovarian 7 carcinomas. GLUT-1 was reported originally as a marker of infantile skin hemangioma.…”

Section: Introductionmentioning

confidence: 99%

GLUT-1 Expression in Cutaneous Basal and Squamous Cell Carcinomas

2015

View full text Add to dashboard Cite

Glucose uptake is a key regulating step in glucose metabolism and is mediated by facilitative glucose transporters (GLUTs), and GLUT-1 is the predominant glucose transporter in many types of human cells. Cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) represent the most common skin cancer in Egypt. The present study aimed at evaluation of the pattern and distribution of GLUT-1 in cutaneous BCC (16 cases) and SCC (16 cases) by means of immunohistochemistry. GLUT-1 was expressed in all SCC (100%) and in 62.5% of BCC. Membranous pattern of GLUT-1 was seen in 62.5% of SCC and 31.25% of BCC. Positivity (P = .02) and percentage (P = .000) of GLUT-1 expression were in favor of SCC in comparison to BCC. The high percentage of GLUT-1 expression was associated with high grade in SCC (P = .03). The immunoreactivity for GLUT-1 was more in the periphery of malignant nests of SCC while it was more in the center of BCC nests. GLUT-1 is overexpressed in cutaneous non-melanoma skin cancer. Its expression in SCC is related to differentiation status, and its expression in BCC is intimately associated with squamous metaplastic areas.

show abstract

“…Compounds possessing peptide mimic as transporter recognition unit can be transported into cancer cells by PEPT1. GluT1 (glucose transporter 1) is overexpressed in cancer cells, particularly in breast cancer cells compared to healthy breast cells [11,12]. Incorporating glucose mimic as transporter recognition unit into novel compounds may develop cell-permeable anti-cancer drugs due to the glucose transport system.…”

Section: Specific Overexpression Of Slc Transporters In Cancer Cellsmentioning

confidence: 99%

Possibilities of Cancer Chemotherapy Based on Transporter-Conscious Drug Design

Tashima¹

2015

J Carcinog Mutagen

View full text Add to dashboard Cite

Cancer chemotherapy is the treatment method which uses drugs to kill cancer cells or to inhibit their growth. In cancer drug discovery or development, not only anti-cancer drug delivery into target cancer cells across the cell membrane but also acquired anti-cancer drug resistance through the overexpression of ATP-binding cassette (ABC) transporters such as MDR1 (p-glycoprotein) in target cancer cells are serious problems to overcome. However, the use of transport system based on solute carrier (SLC) transporters can solve both problems, because it is wellknown that some types of SLC transporters are overexpressed in cancer cells. Thus, transporter-consciously designed drugs can be transported into cells by such overexpressed SLC transporters, so as not to be excreted by MDR1. Therefore, transporter-conscious drug design is very effective in absorption, distribution, excretion, and toxicity of drugs (ADMET) due to transport systems. In this paper, cancer chemotherapy based on transporterconscious drug design is described.

show abstract

Glut-1 Expression Correlates with Basal-like Breast Cancer

Abstract: Our results show that Glut-1 is significantly associated with BLBC and might be a potential therapeutic target for this aggressive subgroup of breast cancer, and this warrants further investigations.

Cited by 71 publications

References 39 publications

Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer

Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer

GLUT-1 Expression in Cutaneous Basal and Squamous Cell Carcinomas

Possibilities of Cancer Chemotherapy Based on Transporter-Conscious Drug Design

Contact Info

Product

Resources

About